Milkhaus Veterinary Products, Inc. Launches Trial of Canine Cancer Therapeutic.Business Editors and Health/Medical Writers DELANSON, N.Y.--(BUSINESS WIRE)--March 21, 2000 Milkhaus Veterinary Products, Inc. ("MVP (Multimedia Video Processor) A high-speed DSP chip from Texas Instruments, introduced in 1994. Officially introduced as the TMS320C80, it combines RISC technology with the functionality of four DSPs on one chip. ") announced today the initiation of its multi-center mast cell tumor A mast cell tumor is a type of tumor consisting of mast cells that is found in many species of animals. It is also known as a mastocytoma, which in human medicine can refer to an accumulation or nodule of mast cells that resembles a tumor. study. MVP gained approval from USDA USDA, n.pr See United States Department of Agriculture. APHIS to proceed with the evaluation of its cancer therapeutic, LDI-100, in canine patients. The company will seek to enroll 90 dogs with mast cell tumors through its five investigational sites. Mast cell tumors are among the most common forms of cancer in dogs. Tumors are usually located within the skin of the limbs or body and can metastasize me·tas·ta·size v. To be transmitted or transferred by or as if by metastasis. Metastasize Spread of cells from the original site of the cancer to other parts of the body where secondary tumors are formed. to vital organs such as the lymph nodes, bone marrow, spleen and liver. Current treatment involves the use of steroids, radiation and chemotherapy and surgery. Such treatment is expensive and often fails to affect a cure. Dr. John McMichael, the company's founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. said: "Many chronic diseases in humans, such as cancer, have animal counterparts. Based on pilot studies, in vitro work, and our successful completion of FDA-authorized human clinical trials, we're optimistic about the outcome of this study. We previously reported that LDI-100 functions by down-regulating the bcl-2 oncogene and inducing apoptosis, whereby malignant cells lose their characteristics of transformation and become susceptible to immune elimination. Favorable results will be useful in furthering our understanding of this mechanism of action and our product addresses an important need in the veterinary market." Milkhaus Veterinary Products, Inc. is a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Milkhaus Laboratory, Inc., a private clinical stage biopharmaceutical company focused on the development of therapeutic agents for chronic diseases. The Company's business strategy is to conduct early stage clinical trials and then license out its products for further development. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion